Maintenance therapy for low-grade lymphomas: has the time come?
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Oncology
Reference54 articles.
1. Update of the FL2000 randomized trial combining rituximab to CHVP–interferon in follicular lymphoma (FL) patients;Foussard;J Clin Oncol,2006
2. Addition of rituximab to first-line MCP (mitoxantrone, chlorambucil, prednisolone) chemotherapy prolongs survival in advanced follicular lymphoma – 4 years follow-up results of a phase III trial of the East German Study Group Hematology and Oncology (OSHO#39);Herold;Blood,2006
3. MabThera (Rituximab) plus cyclophosphamide, vincristine and prednisone (R-CVP) chemotherapy improves survival in previously untreated patients with advanced follicular non-Hodgkin's lymphoma (NHL);Marcus;Blood,2006
4. Front-line combined immuno-chemotherapy (R-CHOP) significantly improves the time to treatment failure and overall survival in elderly patients with advanced stage follicular lymphoma – results of a prospective randomized trial of the Gerlan Low Grade Lymphoma Study Group (GLSG);Buske;Blood,2006
5. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule;Ghielmini;Blood,2004
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Maintenance therapy in follicular lymphoma;Current Opinion in Oncology;2011-09
2. The future of CD20 monoclonal antibody therapy in B-cell malignancies;Leukemia & Lymphoma;2010-04-06
3. How to improve the treatment outcome in chronic lymphocytic leukemia?;Leukemia Research;2010-03
4. Current and Emerging Treatments for Chronic Lymphocytic Leukaemia;Drugs;2009-12
5. Rationale for Consolidation to Improve Progression-Free Survival in Patients with Non-Hodgkin’s Lymphoma: A Review of the Evidence;The Oncologist;2009-10-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3